Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis

Inclusion Criteria:

• Women aged 18 to 36 years (women ≥18 years to <36 years) with endometriosis and / oradenomyosis

• Having benefited from In vitro fertilisation /intracytoplasmic micro-injection withfreeze all and for whom the frozen embryon transfer of a blastocyst is planned

• A normal uterine cavity

• An MRI showing endometriosis and / or adenomyosis during the inclusion visit

• Having signed a consent form

• Being affiliated to a Health Insurance Plan.

Exclusion Criteria:

• Patient aged <18 years and ≥ 36 years

• BMI> 35

• History of implantation failures (≥ 2)

• Endometrial alterations: synechiae, polyps, myomas, hyperplasia, hematometra

• known hydrosalpinx uni or bilateral

• MRI showing no endometriosis or adenomyosis

• Hypersensitivity to GnRH, GnRH analogues, or any of the excipients of Decapeptyl 3mg

• Known hypersensitivity to estradiol

• Known hypersensitivity to progesterone

• Known hypersensitivity to acetylsalicylic acid or other nonsteroidalanti-inflammatory drugs

• Known hypersensitivity to folic acid

• Known hypersensitivity to cefixime or an antibiotic in the cephalosporin group

• Known hypersensitivity to levofloxacin or any other quinolone

• History of tendinopathies related to the administration of fluoroquinolones

• Epilepsy

• Hypersensitivity to contrast agents for MRI

• Known or suspected breast cancer or history of breast cancer

• Known or suspected genital tract cancer or history of genital cancer

• known or suspected estrogen-dependent malignant neoplasms

• Undiagnosed genital haemorrhage

• Untreated endometrial hyperplasia

• History of idiopathic venous thrombo-embolic accident or evolving venousthrombo-embolic event (deep vein thrombosis, pulmonary embolism)

• Recent or evolving arterial thromboembolic stroke (eg angina, myocardial infarction)

• Acute liver disease or history of liver disease, until hepatic tests are normalized

• Severe renal insufficiency

• Severe, uncontrolled heart failure

• Evolutionary gastroduodenal ulcer

• History of asthma caused by the administration of salicylates or substances ofsimilar activity, especially nonsteroidal anti-inflammatory drugs

• GnRH Agonist Decapeptyl administered within 6 months prior to transfer

• To be deprived of liberty or under guardianship

• Pregnancy and breast feeding.